Harvard Bioscience, Inc. Invites You to Join Its First Quarter 2005 Conference Call on the Web
Business Editors/Medical Editors
BIOWIRE2K
HOLLISTON, Mass.--(BUSINESS WIRE)--April 21, 2005--Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce results for the first quarter ended March 31, 2005 after market trading hours on Thursday, May 5, 2005.
At 8:30 a.m. Eastern Time on Friday, May 6, 2005, management will host a conference call to discuss the Company's quarterly results. In addition, management may answer questions concerning business and financial developments and trends, the Company's view on earnings forecasts, and other business and financial matters affecting the Company. Some of the information to be presented on the call or provided in response to questions may contain information that has not previously been disclosed.
The conference call will be simultaneously broadcast over the Internet and can be accessed through the Harvard Bioscience, Inc. website. To listen to the conference call, log on to our website at: www.harvardbioscience.com and click on the Earnings Call icon. Financial and other statistical information presented on the call, including our earnings release, will also be available on the investor relations section of our website. Click on the investor relations' button and then click on the press release or web cast icon, as appropriate. If you are unable to listen to the live web cast, the call will be archived in the investor relations' section of our web site. The live conference call can also be accessed by dialing 800-901-5213 and referencing the pass code of "49967338".
Harvard Bioscience is a global developer, manufacturer and marketer of innovative, enabling tools in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. HBIO sells its products to thousands of researchers in 100 countries through its direct sales force, its 1,100 page catalog, various specialty catalogs and through its distributors, including GE Healthcare (formerly known as Amersham Biosciences), and Fisher Scientific. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Belgium, Austria and Germany and sales offices in France and Canada. For more information, please visit www.harvardbioscience.com.
The statements made in this press release that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements include, but are not limited to, those factors set forth under the heading "Important Factors That May Affect Future Operating Results" in the Company's Annual Report on Form 10K for the fiscal year ended December 31, 2004 or described in the Company's other public filings. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.
--30--MW/bo*
CONTACT: Harvard Bioscience, Inc. David Green, 508-893-8999 President dgreen@harvardbioscience.com
KEYWORD: MASSACHUSETTS INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY EARNINGS CONFERENCE CALLS SOURCE: Harvard Bioscience, Inc.
Copyright Business Wire 2005
